Alamar Biosciences’ mission is to transform the field of proteomics for early detection of cancer and other diseases. Following in the footsteps of genomics, proteomes will usher in a new era of precision health. The human plasma proteome, the complete set of proteins in human blood, has long been recognized as a gold mine of health and disease biomarkers. However, due to the low abundance and wide dynamic range of these proteins in the plasma, most of the plasma proteome has remained inaccessible with current technologies. We are creating the world’s most sensitive proteomics platform to unmask the deepest secrets of our proteome. Our fully automated, high throughput platform will empower new biomarker discoveries for early detection and prevention of common diseases.
Location: United States
Employees: 11-50
Total raised: $178M
Founded date: 2018
Investors 3
| Date | Name | Website |
| 09.05.2026 | Hercules C... | htgc.com |
| - | Illumina V... | illuminaVe... |
| 10.07.2026 | Qiming Ven... | qimingvc.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 12.01.2026 | - | $50M | T. Rowe Pr... |
| 27.02.2024 | Series C | $128M | - |
Mentions in press and media 26
| Date | Title | Description |
| 10.07.2026 | Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ | - |
| 21.04.2026 | Lightcast Secures Major Funding, Redefines Single-Cell Analysis with Envisia Platform | Lightcast, a life science innovator, secured $27 million in funding. ARCH Venture Partners led the round. This capital fuels the 2026 commercial launch of its Envisia™ benchtop platform. Envisia marks a significant leap in single-cell analy... |
| 21.04.2026 | Alamar lists on Nasdaq, giving Qiming its fifth IPO in 2026 | Qiming Venture Partners has recorded its fifth IPO within its portfolio since the start of the year, after Alamar Biosciences officially began trading on Nasdaq on April 17. Founded in 2018, Alamar was established by a team led by scientist... |
| 14.04.2026 | Lightcast Raises $27 Million and Adds Industry Veteran to Accelerate Commercialization of Envisia™ Platform | · Proceeds will help enhance workflows and expand single-cell functional assay portfolio · Brad Crutchfield joins as advisor to support early access growth and global launch CAMBRIDGE, England – April 14, 2026 – Lightcast, a pioneering life... |
| 13.01.2026 | Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer's Disease Research | FREMONT, Calif., Jan. 13, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, is proud to announce the launch of its Research Use Only (... |
| 12.01.2026 | Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team | T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors FREMONT, Calif., ... |
| 10.10.2025 | Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer's Disease Research | New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next generation of assay development. FREMONT, Calif., Oct. 10, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable... |
| 29.07.2025 | Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort | NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 to Power Biomarker Discovery in 23,000 Longitudinal Samples FREMONT, Calif., July 29, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the... |
| 28.07.2025 | Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer's Association International Conference (AAIC) | Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters and Presentations at International Meeting FREMONT, Calif., July 28, 2025 /PRNewswire/ -- Alamar Biosciences, a company pioneering precisio... |
| 10.06.2025 | Alamar Biosciences, Alzheimer's Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer's Disease. | Multi-center project will profile over 40,000 samples using ultra-sensitive NULISA™ technology. FREMONT, Calif., June 10, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of d... |
Show more